Published in World J Gastroenterol on July 21, 2010
Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness. BMC Gastroenterol (2014) 1.47
The cystic fibrosis intestine. Cold Spring Harb Perspect Med (2013) 0.98
Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Sci Rep (2015) 0.76
Fecal Calprotectin, Elastase, and Alpha-1-Antitrypsin Levels After Roux-en-Y Gastric Bypass; Calprotectin Is Significantly Elevated in the Majority of Patients. Obes Surg (2016) 0.75
Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use. Pediatr Rheumatol Online J (2017) 0.75
Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 21.37
The Sydney System: histological division. J Gastroenterol Hepatol (1991) 5.49
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 3.49
Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol (2002) 3.20
Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol (1992) 3.09
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis (2003) 2.79
A simple method for assessing intestinal inflammation in Crohn's disease. Gut (2000) 2.69
Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol (2007) 2.38
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis (2008) 2.04
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol (1997) 1.98
Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci (2009) 1.91
Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther (2008) 1.72
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis (2009) 1.68
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis (2008) 1.65
Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 1.30
Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol (2003) 1.22
Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol (2003) 1.12
Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol (1992) 0.93
Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum (2007) 0.88
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol (2006) 0.85
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology (2009) 4.16
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet (2007) 3.62
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med (2006) 2.55
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (2014) 2.21
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 2.18
Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol (2009) 2.17
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis (2012) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet (2003) 2.08
Reflux symptoms in professional opera choristers. Gastroenterology (2007) 2.03
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Acute cryptogenic liver failure in an untreated coeliac patient: a case report. Eur J Gastroenterol Hepatol (2005) 1.65
Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. Gastrointest Endosc (2003) 1.64
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet treatment correlates with body fat stores. J Clin Gastroenterol (2009) 1.54
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Endometriosis, need for a multidisciplinary clinical setting: the internist's point of view. Intern Emerg Med (2010) 1.53
Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother (2002) 1.53
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Celiac disease associated with autoimmune myocarditis. Circulation (2002) 1.51
Four hundred consecutive total gastrectomies for gastric cancer: a single-institution experience. Arch Surg (2008) 1.48
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
Primary renal angiosarcoma: a rare malignancy. A case report and review of the literature. Urol Oncol (2006) 1.47
Circulating procalcitonin in aseptic carcinoma patients: a specificity study with (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. Clin Chem Lab Med (2010) 1.44
Severe acute hepatitis after resumption of interferon-Beta therapy for multiple sclerosis: a word of caution. Am J Gastroenterol (2007) 1.42
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
[Gastrointestinal stromal tumors]. Ann Ital Chir (2011) 1.41
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol (2008) 1.38
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Oral specific desensitization in food-allergic children. Dig Dis Sci (2007) 1.34
EUS-guided fine-needle tissue acquisition by using a 19-gauge needle in a selected patient population: a prospective study. Gastrointest Endosc (2011) 1.33
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl (2005) 1.30
Acute alcohol intoxication. Eur J Intern Med (2008) 1.29
The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med (2002) 1.25
Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine (2008) 1.23
Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis (2007) 1.21
Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog (2013) 1.19
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology (2007) 1.17
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol (2009) 1.12
Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol (2007) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav (2005) 1.09
Relationship between ghrelin levels, alcohol craving, and nutritional status in current alcoholic patients. Alcohol Clin Exp Res (2006) 1.09
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09